InMed Pharmaceuticals Inc. (MTRI) stock
MTRINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as INM
$15.29−2.21 (-12.66%)
Close on Nov 18, 2026Market cap $83.97MP/E –Yield –
InMed Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
InMed Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2024 was -$7.00M. For fiscal 2024 it was -$7.00M. The highest annual figure on record is -$7.00M in fiscal 2024.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | -$7.00M | – |
| FY2023 | Jun 30, 2023 | -$7.44M | – |
| FY2022 | Jun 30, 2022 | -$15.62M | – |
| FY2021 | Jun 30, 2021 | -$9.79M | – |
| FY2020 | Jun 30, 2020 | -$7.42M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | -$1.03M | – |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -$1.93M | – |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | -$689.75K | – |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -$4.05M | – |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -$5.35M | – |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -$3.32M | – |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -$2.90M | – |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -$1.40M | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -$1.53M | – |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -$2.09M | – |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -$2.40M | – |
See a number that looks wrong?